Poland· PL-100490371

Yorvipath

A palopegteriparatide product containing palopegteriparatidum, registered in Poland by Ascendis Pharma Bone Diseases A/S. The same ATC class is registered in 11 of our 19 countries.

ATC H05AA05

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedYorvipathATCH05AA05REGISTER NO.PL-100490371PACKS LISTED3CHECKEDSeptember 27, 2026

Where it is registered

Palopegteriparatide is registered in 11 of 19 countries.

Countries holding a registration under ATC H05AA05 (palopegteriparatide), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 7 of them publish a price we can compare per daily dose

Palopegteriparatide · ATC H05AA05

11 / 19 countries

  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Palopegteriparatidum
Manufacturer
Ascendis Pharma Bone Diseases A/S
Country
Poland (PL)
ATC code
H05AA05
ATC class
Palopegteriparatide
Defined daily dose
33 mcg, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 3

  • gtin
    05714765032446
  • gtin
    04150188322213
  • gtin
    05714765032316

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/72c43806-7350-453f-b4c7-aef8e33eebec
GET /v1/drugs/72c43806-7350-453f-b4c7-aef8e33eebec?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Roztwór do wstrzykiwań we wstrzykiwaczu",
  "source": "urpl",
  "strength": "294 mcg/0,98 ml",
  "packaging": "05714765032446 ¦ Rpz ¦ EU/1/23/1766/002 ¦ 152237\n2 wstrzykiwacze 0,98 ml ¦ 30 igieł \n¦ UR/Z/4b/073/24 - 04150188322213 ¦ UR/Z/4b/033/25 - 04150188322213 ¦ UR/Z/4b/274/25 - 04150188322213 ¦ UR/Z/4b/119/26 - 05714765032316 ¦ UR/Z/4b/258/26 - 05714765032316",
  "substance": "Palopegteriparatidum 294 mcg/0.98 ml",
  "common_name": "Palopegteriparatidum",
  "pl_product_id": "100490371",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}

See everything about palopegteriparatide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.